Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, the Panum Institute, University of Copenhagen, Copenhagen, Denmark.
Br J Pharmacol. 2013 Dec;170(7):1349-62. doi: 10.1111/bph.12361.
The ghrelin receptor is a 7 transmembrane (7TM) receptor involved in a variety of physiological functions including growth hormone secretion, increased food intake and fat accumulation as well as modulation of reward and cognitive functions. Because of its important role in metabolism and energy expenditure, the ghrelin receptor has become an important therapeutic target for drug design and the development of anti-obesity compounds. However, none of the compounds developed so far have been approved for commercial use. Interestingly, the ghrelin receptor is able to signal through several different signalling pathways including Gαq , Gαi/o , Gα12/13 and arrestin recruitment. These multiple signalling pathways allow for functionally biased signalling, where one signalling pathway may be favoured over another either by selective ligands or through mutations in the receptor. In the present review, we have described how ligands and mutations in the 7TM receptor may bias the receptors to favour either one G-protein over another or to promote G-protein independent signalling pathways rather than G-protein-dependent pathways. For the ghrelin receptor, both agonist and inverse agonists have been demonstrated to signal more strongly through the Gαq -coupled pathway than the Gα12/13 -coupled pathway. Similarly a ligand that promotes Gαq coupling over Gαi coupling has been described and it has been suggested that several different active conformations of the receptor may exist dependent on the properties of the agonist. Importantly, ligands with such biased signalling properties may allow the development of drugs that selectively modulate only the therapeutically relevant physiological functions, thereby decreasing the risk of side effects.
This article is part of a themed section on Neuropeptides. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.170.issue-7.
胃饥饿素受体是一种 7 跨膜(7TM)受体,参与多种生理功能,包括生长激素分泌、增加食物摄入和脂肪积累以及调节奖励和认知功能。由于其在代谢和能量消耗中的重要作用,胃饥饿素受体已成为药物设计和开发抗肥胖化合物的重要治疗靶点。然而,迄今为止开发的化合物均未获得商业用途。有趣的是,胃饥饿素受体能够通过几种不同的信号通路进行信号传递,包括 Gαq、Gαi/o、Gα12/13 和抑制蛋白募集。这些多种信号通路允许进行功能偏向性信号传递,其中一种信号通路可能比另一种信号通路更受选择性配体或受体突变的影响。在本综述中,我们描述了 7TM 受体中的配体和突变如何使受体偏向于偏爱一种 G 蛋白而不是另一种 G 蛋白,或者促进 G 蛋白非依赖性信号通路而不是 G 蛋白依赖性信号通路。对于胃饥饿素受体,已证明激动剂和反向激动剂通过与 Gαq 偶联的途径比与 Gα12/13 偶联的途径更强烈地传递信号。同样,已经描述了一种促进 Gαq 偶联而不是 Gαi 偶联的配体,并且已经提出受体可能存在几种不同的活性构象,这取决于激动剂的性质。重要的是,具有这种偏向性信号传递特性的配体可能允许开发仅选择性调节具有治疗相关性的生理功能的药物,从而降低副作用的风险。
本文是神经肽专题的一部分。要查看该部分中的其他文章,请访问 http://dx.doi.org/10.1111/bph.2013.170.issue-7.